Seeking Alpha

David Greene's  Instablog

David Greene
Send Message
Trading and investing full time for personal account and consulting with a money manager firm with assets of over $55 Million. Worked on Wall Street for 18 years at two wirehouses and one boutique investment banking firm. Investment discipline includes taking advantage of Wall Street's tendency... More
My blog:
sirf.com
  • Another Abstract at ASCO Highlights Efficacy of CTT's Calmare Pain Therapy System in Cancer Patients 0 comments
    May 27, 2010 11:17 AM | about stocks: ABT, CBST, AFFX, ARIA, ARYX, BAX, BCR, BDX, BSX, CELG, CLDX, CMN, CNMD, CTIC, CTT-RETIRED, CYBX, DCTH, DNDN, ENZ, ETRM, GE, GILD, GNVC, GSK, HAE, IART, IBPI, IRIX, JNJ, KOOL, MAKO, MDT, MLNM, NVS, PDLI, PFE, PGNX, PHG, PMTI, RDNT, RTN, SOMX, SQNM, STJ, STS, SYK, VOLC, VVUS
     

    Another abstract on a study utilizing Competitive Technologies' (NYSE Amex: CTT) Calmare(NYSE:R) Pain Management technology was posted on the ASCO site (asco.org)-- http://abstract.asco.org/AbstView_74_50422.html

    Clinical investigators in Italy conducted a 16 month independent clinical study to evaluate the efficacy of the Calmare pain therapy treatment to decrease and manage chronic pain associated with cancer (CCP) experienced by approximately 50 percent of cancer patients and up to 70 percent suffering with cancer in its advanced stages. 

    As noted in the abstract summary, "Preliminary results have shown the effectiveness of Scrambler therapy, which uses electroanalgesia to neuromodulate cancer-related neuropathic pain. The Scrambler machine is supported by a multiprocessor computer capable of simulating 5 artificial neurons that send out signals identified by the central nervous system as 'no pain.' In this way the Scrambler information can be conveyed through electrodes to nerve fibres involved in the production or transmission of the pain signal."

    The results indicated a decrease from an average of 4.7 (on the pain scale) to 2.5 at the end of the second week of treatment. The treatment regimen involved one 30 minute session per day for five consecutive days and repeated for the following week of five days.

    The study included testing for duration of results--showing a median VAS score of 2.6 two weeks after the last treatment. Patients with severe pain "showed a decrease at base line from 6.5 to 3.5." An interesting result on a sales and marketing basis for CTT is that 97% of the patients, knowing their results, said they would repeat the treatments.

    Obviously, the more clinical data available to the medical community on the effectiveness of CTT's chronic pain therapy, the more the company benefits in both credibility and awareness--which obviously helps with CTT's business plan on building out its distribution network.


    Disclosure: Long CTT
Back To David Greene's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

  • Digesting The GMO Food Controversy And What It Means For Your Investment Portfolio http://seekingalpha.com/a/1dh8b
    Jul 10, 2014
  • European markets cratered on Labor Day, setting the stage for a 250-300 point drop in the DOW when traders return on Tuesday.
    Sep 5, 2011
  • Competitive Technologies (CTTC, $1.75) for continued strength after chronic pain technology is highlighted on two TV morning shows tomorrow.
    Mar 14, 2011
More »

Latest Comments


Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.